Syphla-Chek: a qualitative study.

A qualitative evaluation of the newly marketed Syphla-Chek Test (Hyland, Div. of Travenol Laboratories, Inc., Costa Mesa, Calif.), a macroscopically read, nontreponemal card test, was undertaken in order to further evaluate the validity of this procedure as an aid in the diagnosis of syphilis. A total of 1,074 randomly selected sera submitted to the Texas Department of Health Resources for routine analysis, for confirmational analysis, and as a result of problems in analysis, were examined using the Venereal Disease Research Laboratory (VDRL) slide test, the Rapid Plasma Reagin (circle) Card Test (RPRCT), Syphla-Chek Test, and the fluorescent treponemal antibody absorption (FTA-ABS) test. Comparison of the reagin testing procedures studied versus the FTA-ABS procedure led to the following order of agreement with FTA-ABS reactive results: Syphla-Chek, 88.8%; RPRCT, 87.1%; and VDRL, 83.2%. Agreement with FTA-ABS nonreactive results was in order: RPRCT, 86.7%; Syphla-Chek, 79.6%; and VDRL, 78.7%. The relatively few minor procedural problems encountered with the Syphla-Chek Test during this study are also discussed.